Home Cart Sign in  
Chemical Structure| 1152107-25-9 Chemical Structure| 1152107-25-9

Structure of Lanopepden
CAS No.: 1152107-25-9

Chemical Structure| 1152107-25-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK-1322322 is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 has bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log (10) decrease in the number of CFU/mL at 4× MIC within 24 h in 29 of the 33 strains tested.

Synonyms: GSK 1322322

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lanopepden

CAS No. :1152107-25-9
Formula : C22H34FN7O4
M.W : 479.55
SMILES Code : O=CN(C[C@@H](CC1CCCC1)C(NNC2=NC(C)=NC(N3C[C@@]4([H])COCCN4CC3)=C2F)=O)O
Synonyms :
GSK 1322322

Safety of Lanopepden

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01953809 Infections, Bacterial Phase 1 Withdrawn(Emerging GSK1322322 ... More >>pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk benefit profile and led to a termination) Less << March 2015 -
NCT01209078 Skin Infections, Bacterial Phase 2 Completed - United States, Alabama ... More >> GSK Investigational Site Anniston, Alabama, United States, 36207 United States, California GSK Investigational Site Chula Vista, California, United States, 91911 GSK Investigational Site La Mesa, California, United States, 91942 GSK Investigational Site Long Beach, California, United States, 90813 GSK Investigational Site Oceanside, California, United States, 92056 United States, Hawaii GSK Investigational Site Honolulu, Hawaii, United States, 96813 United States, Pennsylvania GSK Investigational Site West Reading, Pennsylvania, United States, 19611 Less <<
NCT01803399 Infections, Bacterial Phase 1 Withdrawn(Emerging GSK1322322 ... More >>pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk benefit profile and led to a termination) Less << December 2014 -
NCT01818011 Infections, Bacterial Phase 1 Terminated(Emerging GSK1322322... More >> pre-clinical data ID'd potentially reactive metabolites previously not seen that changed the risk benefit profile and led to a termination) Less << - United States, Kansas ... More >> GSK Investigational Site Overland Park, Kansas, United States, 66211 Less <<
NCT00924911 Infections, Bacterial Phase 1 Completed - United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less <<
NCT00896558 Infections, Bacterial Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 Less <<
NCT01663389 Infections, Bacterial Phase 1 Completed - United States, Minnesota ... More >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 Less <<
NCT01610388 Infections, Bacterial Phase 1 Completed - United States, Minnesota ... More >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 Less <<
NCT01209078 - Completed - -
NCT01648179 Infections, Bacterial Phase 1 Completed - United States, Minnesota ... More >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.43mL

2.09mL

1.04mL

20.85mL

4.17mL

2.09mL

References

 

Historical Records

Categories